Alzheimer's Disease Assessment Scale--Cognitive Subscale; Turkish Version

2006 ◽  
Author(s):  
H. Mavioglu ◽  
M. Gedizlioglu ◽  
S. Akyel ◽  
T. Aslaner ◽  
E. Eser
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Assessment Scale ◽  
Disease Assessment ◽  
Turkish Version ◽  
Cognitive Subscale

Validation of the Hungarian version of Alzheimer’s Disease Assessment Scale – Cognitive Subscale

2012 ◽  
Vol 153 (12) ◽  
pp. 461-466 ◽  
Author(s):  
Magdolna Pákáski ◽  
Gergely Drótos ◽  
Zoltán Janka ◽  
János Kálmán
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mental State ◽  
Mini Mental State Examination ◽  
Assessment Scale ◽  
Disease Assessment ◽  
Control Subjects ◽  
Cognitive Subscale ◽  
State Examination ◽  
Hungarian Version

The cognitive subscale of the Alzheimer’s Disease Assessment Scale is the most widely used test in the diagnostic and research work of Alzheimer’s disease. Aims: The aim of this study was to validate and investigate reliability of the Hungarian version of the Alzheimer’s Disease Assessment Scale in patients with Alzheimer’s disease and healthy control subjects. Methods: syxty-six patients with mild and moderate Alzheimer’s disease and 47 non-demented control subjects were recruited for the study. The cognitive status was established by the Hungarian version of the Alzheimer’s Disease Assessment Scale and Mini Mental State Examination. Discriminative validity, the relation between age and education and Alzheimer’s Disease Assessment Scale, and the sensitivity and specificity of the test were determined. Results: Both the Mini Mental State Examination and the Alzheimer’s Disease Assessment Scale had significant potential in differentiating between patients with mild and moderate stages of Alzheimer’s disease and control subjects. A very strong negative correlation was established between the scores of the Mini Mental State Examination and the Alzheimer’s Disease Assessment Scale in the Alzheimer’s disease group. The Alzheimer’s Disease Assessment Scale showed slightly negative relationship between education and cognitive performance, whereas a positive correlation between age and Alzheimer’s Disease Assessment Scale scores was detected only in the control group. According to the analysis of the ROC curve, the values of sensitivity and specificity of the Alzheimer’s Disease Assessment Scale were high. Conclusions: The Hungarian version of the Alzheimer’s Disease Assessment Scale was found to be highly reliable and valid and, therefore, the application of this scale can be recommended for the establishment of the clinical stage and follow-up of patients with Alzheimer’s disease. However, the current Hungarian version of the Alzheimer’s Disease Assessment Scale is not sufficient; the list of words and linguistic elements should be selected according to the Hungarian standard in the future. Orv. Hetil., 2012, 153, 461–466.

COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDY

2019 ◽  
pp. 1-5
Author(s):  
T.M. Solomon ◽  
J.M. Barbone ◽  
H.T. Feaster ◽  
D.S. Miller ◽  
G.B. deBros ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Adult Population ◽  
Prospective Trial ◽  
Electronic Version ◽  
Assessment Scale ◽  
Disease Assessment ◽  
Cognitive Subscale ◽  
Interclass Correlation ◽  
Rater Error

The Alzheimer’s Disease Assessment Scale (ADAS-Cog) has become the de facto gold-standard for assessing the efficacy of putative anti-dementia treatments. There has been an increasing interest in providing greater standardization, automation, and administration consistency to the scale. Recently, electronic versions of the ADAS-Cog (eADAS-Cog) have been utilized in clinical trials and demonstrated significant reductions in frequency of rater error as compared to paper. In order to establish validity of the electronic version (eADAS-Cog), 20 subjects who had received a diagnosis of probable Alzheimer’s disease (AD) at a private US Memory Clinic completed a single-center, randomized, counterbalanced, prospective trial comparing a version of the eADAS-Cog to the standard paper scale. Interclass Correlation Coefficient on total scores and Kappa analysis on domain scores yielded high agreement (0.88 – 0.99). Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect. Overall, this study establishes adequate concurrent validity between the ADAS-Cog and eADAS-Cog among an adult population with diagnosed AD.

An Arabic Version of the Cognitive Subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data

2017 ◽  
Vol 60 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Sonia Ben Jemaa ◽  
Neila Attia Romdhane ◽  
Amel Bahri-Mrabet ◽  
Adel Jendli ◽  
Didier Le Gall ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Normative Data ◽  
Assessment Scale ◽  
Disease Assessment ◽  
Arabic Version ◽  
Cognitive Subscale

CHOLINESTERASE INHIBITORS IN ALZHEIMER’S DISEASE

2015 ◽  
Vol Ano 5 ◽  
pp. 18-23
Author(s):  
KELLEN KLEIN PEREIRA ◽  
VALESKA MARINHO
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Assessment Scale ◽  
Disease Assessment ◽  
Cognitive Subscale

A doença de Alzheimer (DA) é a causa mais comum de demência, caracterizada por início insidioso e curso progressivo, com declínio cognitivo, comprometimento da autonomia e da capacidade de realização de atividades de vida diária, alterações de humor e de comportamento. Ao longo do curso da doença, podem ser observadas manifestações clínicas de diversas naturezas: cognitivas, com declínio na capacidade mnêmica, de linguagem, visuoespacial, habilidades construcionais, função executiva, entre outras; comportamentais, como depressão, ansiedade, comportamento violento/agitado; insônia; comprometimento da capacidade de realização de atividades de vida diária; impacto sobre independência e qualidade de vida do paciente e seu cuidador. Atualmente, o tratamento da DA se baseia no uso de inibidores da colinesterase, com a proposta de estabilizar ou alentecer o curso da doença. As evidências disponíveis sugerem uma melhora média de -2,7 pontos (intervalo de confiança de 95%: -3,0 a -2,3) na faixa de 70 pontos na Alzheimer’s Disease Assessment Scale- Cognitive Subscale (ADAS-cog) por um período de 6 meses a 1 ano em pacientes com demência leve, moderada e grave, além de melhor controle dos sintomas comportamentais associados. Este artigo revisa dados recentes sobre o uso de anticolinesterásicos na DA, o momento de sua introdução, duração do tratamento e principais marcadores de eficácia.

Sign in / Sign up

Export Citation Format

Share Document